UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 21, 2007
VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)
| | | | |
| DELAWARE | | 0-26483 | | 94-3236309 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification Number) |
349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CALIFORNIA 94080
(Address of Principal Executive Offices)
Registrant’s Telephone Number, Including Area Code: (650) 624-1000
1000 MARINA BOULEVARD, SUITE 200, BRISBANE, CALIFORNIA 94005
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 5—CORPORATE GOVERNANCE AND MANAGEMENT
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 27, 2007, VaxGen, Inc. (the “Company”) announced that, effective on the earlier of August 1, 2007 or the date upon which the Company recruits her replacement, Eve Slater will resign from the Board of Directors of the Company. Dr. Slater recently accepted a management position at a large pharmaceutical company which required that she relinquish all of her directorships. Dr. Slater’s resignation is not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | | | | VaxGen, Inc. |
| | | | (Registrant) |
| | |
| Dated: March 27, 2007 | | By: | | /s/ Matthew J. Pfeffer |
| | | | Matthew J. Pfeffer |
| | | | Senior Vice President, Finance and |
| | | | Administration and Chief Financial Officer |
